MCM2

Across TCGA pan-cancer cohorts, MCM2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MCM2 data layer compared with 30 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher MCM2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MCM2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

KICH, PAAD, and KIRC are the cancer types where MCM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
PAAD	OS	Median	All	0.110	0.640	<.001	12	view →
KIRC	OS	Median	All	0.146	0.657	.001	12	view →
SKCM	DFS	Median	III,IV	1.000	0.462	.013	10	view →
LUSC	OS	Median	All	0.333	0.663	.022	8	view →
UCEC	DFS	Median	All	0.952	0.828	.025	6	view →
LUAD	OS	Median	II,III,IV	0.090	0.677	<.001	6	view →
GBM	OS	Median	All	1.000	0.257	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MCM2–KICH (DFS)

Open the KICH breakdown →